MDxHealth (MDXH) investor relations material

Growth fundamentals and market opportunity

• Comprehensive prostate cancer menu supported by robust clinical data and established reimbursement.

• Expansion through acquisitions of Genomic Prostate Score and ExoDx Prostate Test.

• Over 500,000 patients tested and a commercial team of over 80 people.

• Addressable U.S. market opportunity estimated at $4.9B, including prostate and urinary tract infection diagnostics.

• Menu expansion and decentralization opportunities identified for future growth.

Product portfolio and clinical evidence

• ExoDx Prostate Test is a non-invasive, urine-based assay with 91% NPV for clinically significant prostate cancer, included in NCCN and AUA guidelines.

• Confirm mdx is an epigenetic test with 96% NPV for aggressive prostate cancer, validated in over 55 studies and included in EAU and NCCN guidelines.

• GPS mdx analyzes gene activity to guide treatment for localized prostate cancer, validated in over 20 studies and predicts adverse pathology and mortality.

• Resolve mdx offers advanced molecular UTI testing, identifying pathogens and resistance genes with results in 24-48 hours.

• Monitor mdx in development as a non-invasive surveillance tool for prostate cancer, targeting a 1.5M annual patient market.

Financial performance and guidance

• 2025 total revenue reached $107.9M, up 20% year-over-year; gross profit rose 26% to $69.6M.

• Net loss for 2025 was $33.5M, a 12% improvement from the prior year; adjusted EBITDA improved by 92%.

• Gross margin increased to 64.5% in 2025.

• 2026 revenue guidance set at $137-140M, representing approximately 28% growth at the midpoint.

• Multi-billion-dollar market opportunity reinforced by recent acquisitions and expanded payer coverage.